Scottish Medicines Consortium recommends new schizophrenia treatment

 The Scottish Medicines Consortium (SMC) has recommended the use of paliperidone palmitate 3-monthly injection (Trevicta) for use in NHS Scotland without restriction for the maintenance treatment of schizophrenia. The drug is for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product. This new formulation of paliperidone palmitate is administered every three months and is available at pro-rata cost to the monthly formulation. The positive recommendation of paliperidone palmitate 3-monthly injection by the SMC is an important step forward for people living with schizophrenia in Scotland, who will now have routine access